Please assess the completion status of the following clinical trial:

Trial Title: Efficiency, Safety and Portability of Neovasculgen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age more than 40 years;~* a history of stable claudication for at least 3 months;~* stage 2 to 3 chronic ischemia according to Fontaine classification (modified by A. V. Pokrovsky);~* presence of hemodynamically significant (stenosis \>70% and/or occlusion) diffuse lesions of the interior and (or) posterior tibial arteries (distal lesion);~* voluntary informed consent signed and dated by the patient.~Exclusion Criteria:~* chronic lower limb ischemia of nonatherosclerotic genesis; stage 4 chronic ischemia according to Fontaine classification modified by A. V. Pokrovsky (ischemic ulcers and necrotic lesions);~* severe concomitant pathology with life expectancy \<1 year;~* infectious diseases, history of cancer, or suspected malignancy;

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Neovasculgen (Type: EXPERIMENTAL): DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
- Control (Type: NO_INTERVENTION): Control therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).